

CITATION REPORT

List of articles citing

Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality

DOI: 10.1016/j.jash.2014.03.003

Journal of the American Society of Hypertension, 2014, 8, 405-13.

Source: <https://exaly.com/paper-pdf/58908773/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
101	Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the REasons for Geographic and Racial Differences in Stroke study. 2014 , 64, 465-71		45
100	Device-based approaches for renal nerve ablation for hypertension and beyond. 2015 , 6, 193		10
99	Quality of Life in Treatment-Resistant Hypertension. 2015 , 17, 61		6
98	Differential Outcomes by Race and Ethnicity in Patients with Coronary Heart Disease: A Contemporary Review. 2015 , 9, 1		11
97	Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. 2015 , 17, 541		15
96	Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease. 2015 , 66, 998-1005		34
95	The double challenge of resistant hypertension and chronic kidney disease. 2015 , 386, 1588-98		108
94	Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial. 2015 , 170, 986-994.e523		5
93	Design, Synthesis and ex vivo Study of the Vasorelaxant Activity Induced by Isosteric Derivatives of Dihydropyridines (NH- \odot). 2016 , 13, 353-359		0
92	Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance. 2016 , 46, 593-600		12
91	Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care. 2016 , 29, 976-83		6
90	Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. 2016 , 67, 1085-92		37
89	Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension. 2016 , 18, 817-24		15
88	Resistant Hypertension and Susceptible Outcomes: Exploring the Benefits of Aggressive Blood Pressure Control. 2016 , 18, 40-2		2
87	Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic And Racial Differences in Stroke study. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 578-586.e5		11
86	Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 838-846		12
85	Prevalence of electrocardiographic abnormalities based on hypertension severity and blood pressure levels: the REasons for Geographic and Racial Differences in Stroke study. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 702-713.e4		1

84	Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014. 2016 , 68, 1349-1354	25
83	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. 2016 , 25, 996-1003	12
82	Longitudinal Effect of CPAP on BP in Resistant and Nonresistant Hypertension in a Large Clinic-Based Cohort. 2016 , 149, 747-55	14
81	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 307-17	20
80	Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?. 2016 , 18, 25	6
79	Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk. 2016 , 67, 275-7	1
78	Improving management of resistant hypertension: Rationale and protocol for a cluster randomized trial addressing physician managers in primary care. 2016 , 47, 109-14	1
77	Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. 2016 , 30, 191-6	13
76	Low Blood Pressure Is Associated With Greater Risk for Cardiovascular Events in Treated Adults With and Without Apparent Treatment-Resistant Hypertension. 2017 , 19, 241-249	9
75	Refractory versus resistant hypertension. 2017 , 26, 14-19	15
74	Resistant Hypertension: Mechanisms and Treatment. 2017 , 19, 56	20
73	National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. 2017 , 186, 29-39	7
72	Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. 2017 , 6,	20
71	Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. 2017 , 7, e016692	7
70	Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. 2017 , 390, 2655-2661	56
69	Resistant Hypertension and Outcomes in Patients with and Without Chronic Kidney Disease. 2017 , 59-75	
68	Resistant Hypertension in Chronic Kidney Disease. 2017 ,	0
67	Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease. 2017 , 2, 180-191	2

66	The Effect of Renal Denervation on Plasma Adipokine Profile in Patients with Treatment Resistant Hypertension. 2017 , 8, 369	8
65	Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. 2018 , 32, 487-493	5
64	Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. 2018 , 43, 422-438	13
63	Cardiovascular outcome in treatment-resistant hypertension: results from the Swedish Primary Care Cardiovascular Database (SPCCD). 2018 , 36, 402-409	18
62	Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease. 2018 , 36, 143-150	12
61	Predicting the risk of apparent treatment-resistant hypertension: a longitudinal, cohort study in an urban hypertension referral clinic. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, 809-817	1
60	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. 2018 , 72, e53-e90	333
59	Chemometric-Assisted Spectrophotometric Method for the Simultaneous Quantitative Determination of Ezetimibe and Simvastatin in Their Combined Dosage Forms. 2018 , 101, 1015-1020	0
58	Prognosis of patients with apparent treatment-resistant hypertension-a feasibility study. 2018 , 4, 43	0
57	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. 2018 , 131, 1463-1472.e7	12
56	Age- and body weight-dependent association between sleep duration and hypertension in US adults: findings from the 2014-2017 National Health Interview Survey. 2019 , 5, 509-513	10
55	New Molecules for Treating Resistant Hypertension: a Clinical Perspective. 2019 , 21, 80	1
54	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. 2019 , 32, 1146-1153	2
53	Association Between Sleep Apnea and Blood Pressure Control Among Blacks. 2019 , 139, 1275-1284	30
52	Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. 2019 , 21, 825-834	8
51	Anandamide-nanoformulation obtained by electrospraying for cardiovascular therapy. 2019 , 566, 1-10	12
50	Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES). 2019 , 20, 138	10
49	Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. 2019 , 17, 83	4

48	Treatment of Resistant and Refractory Hypertension. 2019 , 124, 1061-1070	50
47	The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?. 2019 , 37, 1148-1153	76
46	Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension. 2019 , 37, 398-405	4
45	[Resistant hypertension: An update]. 2019 , 36, 44-52	2
44	Prognostic Importance of Resistant Hypertension in Patients With Type 2 Diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. 2020 , 43, 219-227	9
43	Renal denervation: Alternative treatment options for hypertension?. 2020 , 63, 51-57	1
42	Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus. 2020 , 38, 45-51	2
41	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. 2020 , 75, 246-256	17
40	Decreased stroke risk with combined traditional Chinese and western medicine in patients with ischemic heart disease: A real-world evidence. 2020 , 99, e22654	2
39	Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients. 2020 , 22, 2093-2102	6
38	Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. 2020 , 76, 1600-1607	3
37	Optimizing identification of resistant hypertension: Computable phenotype development and validation. 2020 , 29, 1393-1401	3
36	Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study. 2020 , 76, 1953-1961	0
35	Predictors of Resistance Hypertension and Achievement of Target Blood Pressure Levels in Patients with Resistant Hypertension. 2020 ,	
34	Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system. 2020 , 38, 1603-1611	3
33	Obesity predicts persistence of resistant hypertension after surgery in patients with primary aldosteronism. 2020 , 93, 229-237	4
32	Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. 2021 , 77, 72-81	6
31	Resistant Hypertension in People With CKD: A Review. 2021 , 77, 110-121	14

30	Risk of fatal and nonfatal coronary heart disease and stroke events among adult patients with hypertension: basic Markov model inputs for evaluating cost-effectiveness of hypertension treatment: systematic review of cohort studies. 2021 , 12, 283-302	1
29	Uncontrolled arterial hypertension: main causes, features of pathogenesis and approaches to treatment. 2021 , 18, 13-18	3
28	Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension. 2021 , 77, 699-706	3
27	Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease. 2021 , 334, 135-141	4
26	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. 2021 , 78, 376-386	1
25	The effect of resistant hypertension on in-hospital mortality in patients hospitalized with COVID-19. 2021 ,	2
24	Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study. 2021 , 23, 1887-1896	1
23	Primary aldosteronism: a common cause of resistant hypertension. 2017 , 189, E773-E778	24
22	Endovascular baroreflex amplification for resistant hypertension: what you need to know. 2020 , 16, 151-158	1
21	Resistant and refractory arterial hypertension: similarities and differences, new approaches to diagnosis and treatment. 2018 , 15, 11-13	1
20	Association of treatment-resistant hypertension defined by home blood pressure monitoring with cardiovascular outcome. 2021 ,	7
19	The Impact of Uncontrolled Hypertension on the Heart. 2016 , 129-137	
18	Achieving control of resistant hypertension: Not just the number of blood pressure medications. 2019 , 9, 1-16	
17	Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure. 2020 , 13, 83-87	1
16	Resistant Hypertension and Risk of Adverse Events in Individuals With Type 1 Diabetes: A Nationwide Prospective Study. 2020 , 43, 1885-1892	4
15	Clinical features and course of arterial hypertension in patients with its various forms. 2021 , 18, 140-146	2
14	Clinical Characteristics of Resistant vs. Refractory Hypertension in a Population of Hypertensive Afrodescendants. 2020 , 115, 31-39	2
13	Clinical characteristics, target organ damage and associate risk factors of resistant hypertension determined by ambulatory blood pressure monitoring in patients aged ≥30 years. 2017 , 14, 308-314	2

12	Refractory versus resistant hypertension: Novel distinctive phenotypes. 2017 , 3,	11
11	Epidemiology of Resistant Hypertension in Canada.. 2022 ,	4
10	The Burden of Resistant Hypertension Across the World.. 2022 , 24, 55	1
9	The incidence of cardiovascular and cerebrovascular complications in patients with uncontrolled hypertension. 2022 , 94, 94-99	1
8	Apparent Treatment-Resistant Hypertension Among Stroke Survivors: A Transcontinental Study assessing impact of race and geography.. 2022 ,	0
7	Blood Pressure Polygenic Scores Are Associated With Apparent Treatment-Resistant Hypertension.. 2022 , 101161CIRCGEN121003554	0
6	Resistant hypertension is associated with an increased cardiovascular risk compared to patients controlled on a similar multi-drug regimen.	
5	Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta-Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension. 2022 , 79, 2305-2315	0
4	Correlations Of Adenosine Deaminase Activity In The Plasma Of Diabetic Patients With Arterial Hypertension. 144-160	0
3	The many faces of hypertension in individuals with type 1 diabetes. 2023 , 197, 110564	0
2	Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry.	0
1	Clinical characteristics and outcomes of Chinese patients with coronary heart disease and resistant hypertension. 2023 , 25, 350-359	0